Etalocib

From WikiMD's Wellnesspedia

Etalocib is a drug that was under development for the treatment of cancer. It was being developed by Eli Lilly and Company and was in Phase II clinical trials when development was discontinued.

Mechanism of Action[edit | edit source]

Etalocib is a selective inhibitor of the enzyme COX-2. COX-2 is an enzyme that is often overexpressed in cancer cells, leading to increased production of prostaglandins that promote tumor growth and angiogenesis. By inhibiting COX-2, etalocib was intended to slow or stop the growth of cancer cells.

Clinical Trials[edit | edit source]

Etalocib was in Phase II clinical trials for the treatment of colorectal cancer and non-small cell lung cancer. However, the development of the drug was discontinued due to lack of efficacy.

Side Effects[edit | edit source]

The most common side effects reported in clinical trials were nausea, vomiting, and diarrhea. Other side effects included fatigue, anemia, and neutropenia.

See Also[edit | edit source]


Etalocib Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD